The Indian Pharmaceutical Market (IPM) has entered a definitive "Gold Rush" phase. The launch of Semaglutide branded generics in late March 2026 has served as a primary catalyst for a historic shift in metabolic health therapy. While the broader market maintains a healthy 10.1% monthly value growth (reaching ₹20,012 Cr), the real story lies in the structural disruption of the chronic therapy segment.
1. The GLP-1 Paradox: Value vs. Volume
The most significant trend is the explosive entry of Semaglutide branded generics. Within just 10 days of the generic launch (March 21st–31st), the market shifted dramatically:
- The Unit Explosion: Total Semaglutide units (solids and injectables) surged to 157,000 in March. Normalized to 30 days, this represents a >2X jump in units.
- Phenomenal Injectable Jump: The shift is most visible in injectables, which saw an actual unit jump to 63,000 in March, a normalized ~6X increase over February 2026.
- The Value Gap: Because generic pricing is extremely economical, the jump in monthly value was <2X, even as unit adoption skyrocketed.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
